Search - tctmd.com

Displaying 1 - 20 of 661

Sort: Relevancy | Date

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Daily News

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

Caitlin E. Cox

March 19, 2026

News Daily News

Lp(a) and CAC Levels Independently Predict Long-term ASCVD Risk

Yael L. Maxwell

March 19, 2026

News Daily News

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Michael O'Riordan

March 13, 2026

News Daily News

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Michael O'Riordan

March 03, 2026

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Advertisement

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

What’s Going to Be Hot at ACC 2026

Positive Top-line Results for Retatrutide in Diabetes: TRANSCEND-T2D-1

Lp(a) and CAC Levels Independently Predict Long-term ASCVD Risk

Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines

Healthy Lifestyle Plus GLP-1s Yields Bigger CV Reduction Than Drugs Alone

Side Effects of Statins Might Be Overstated: CTT Collaboration

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content